Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Apr 1.

Published in final edited form as: J Allergy Clin Immunol. 2013 Dec 22;133(4):1162–1174.e4. doi: 10.1016/j.jaci.2013.10.036

The effects of R256 treatment during primary allergen challenge on the development of allergen-induced AHR and airway inflammation. (A) The indicated doses of R256 were orally administered during the allergen challenge phase as described in Materials and Methods. Two weeks after the last allergen sensitization, mice were exposed to 3 consecutive days of allergen challenge followed by assessments of airway responsiveness and BAL/lung tissue sampling 48 hrs after the last OVA challenge. (B) Lung resistance (RL). (C) BAL cell composition, (D) goblet cell metaplasia. (E) Representative images show (a) PBS/OVA+vehicle, (b) OVA/OVA+vehicle, (c) OVA/OVA+R256 (10 mg/kg), (d) OVA/OVA+R256 (25 mg/kg), (e) OVA/OVA+R256 (50 mg/kg). (F) Cytokine levels, and (G) eotaxin levels in BAL fluid collected at 48 and 6 hrs after final OVA challenge. The data for each group were expressed as means±SEM. The results are from 3 independent experiments with 3 mice per group, n=9. *p<0.05 and **p<0.01 compared to OVA/OVA+vehicle-treated group.

The effects of R256 treatment during primary allergen challenge on the development of allergen-induced AHR and airway inflammation. (A) The indicated doses of R256 were orally administered during the allergen challenge phase as described in Materials and Methods. Two weeks after the last allergen sensitization, mice were exposed to 3 consecutive days of allergen challenge followed by assessments of airway responsiveness and BAL/lung tissue sampling 48 hrs after the last OVA challenge. (B) Lung resistance (RL). (C) BAL cell composition, (D) goblet cell metaplasia. (E) Representative images show (a) PBS/OVA+vehicle, (b) OVA/OVA+vehicle, (c) OVA/OVA+R256 (10 mg/kg), (d) OVA/OVA+R256 (25 mg/kg), (e) OVA/OVA+R256 (50 mg/kg). (F) Cytokine levels, and (G) eotaxin levels in BAL fluid collected at 48 and 6 hrs after final OVA challenge. The data for each group were expressed as means±SEM. The results are from 3 independent experiments with 3 mice per group, n=9. *p<0.05 and **p<0.01 compared to OVA/OVA+vehicle-treated group.